ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatologists Saw a Gain in Compensation in 2020

Carina Stanton  |  September 22, 2021

Although patient volume temporarily declined due to the COVID-19 pandemic, rheumatologists saw a larger increase in compensation in 2020 than in 2019, according to a recent Medscape survey.

Tocilizumab Effective for Early SSc-Associated Interstitial Lung Disease

Lara C. Pullen, PhD  |  September 22, 2021

Treatment with tocilizimab preserved lung function in patients with systemic sclerosis (SSc) and interstitial lung disease (ILD) regardless of a patient’s level of lung involvement, according to a recent study.

Oral CBD Fails to Relieve Pain from Hand OA & PsA

Reuters Staff  |  September 21, 2021

NEW YORK (Reuters Health)—Lower doses of cannabidiol (CBD) failed to provide any meaningful reduction in pain when added to other analgesic therapy in patients with hand osteoarthritis (OA) or psoriatic arthritis (PsA) in a randomized, placebo-controlled study from Denmark.1 Writing in the journal, Pain, Jonathan Vela, MD, and colleagues of Aalborg University note that CBD…

Inspired by Healthcare Disparities to Advocate for Change

Leslie Mertz, PhD  |  September 21, 2021

Seeing the challenges her rural patients faced in accessing specialty care, Amanda Schnell, MD, was inspired to make advocacy an integral part of her work at the University of Alabama at Birmingham.

FDA Grants Octapharma 7-Year Market Exclusivity for Octagam 10%

Michele B. Kaufman, PharmD, BCGP  |  September 15, 2021

The FDA has granted a seven-year marketing exclusivity for Octagam 10%, a 10% solution of a human intravenous immunoglobulin (IVIG) that treats adults with dermatomyositis.

Rituximab for Children with Lupus Nephritis

Lorraine L. Janeczko  |  September 15, 2021

NEW YORK (Reuters Health)—Pediatric rheumatologists and nephrologists appear to differ in their treatment choices for children who have lupus nephritis (LN), with rheumatologists more likely to prescribe rituximab, results of a small survey suggest. “This study highlights the importance of collaborative effort in developing CTPs (Consensus Treatment Plans) for pediatric LN,” the authors write in…

New ACR Subcommittee Will Advance Diversity, Equity & Inclusion

Susan Bernstein  |  September 7, 2021

The group’s goals include workforce diversification and inclusive speaker recruitment.

Washington Pediatric Rheumatologists Eligible for Loan Forgiveness

Joseph Cantrell, JD  |  September 3, 2021

The 2021–23 Washington budget enables consideration of pediatric rheumatologists for state loan forgiveness programs during the 2019–21 and 2021–23 cycles, making it the first state to include any rheumatologists in its loan forgiveness programs.

ACR Guidance on Tocilizumab Allocation During Shortage

From the College  |  September 1, 2021

In June, the U.S. Food & Drug Administration (FDA) issued an emergency use authorization (EUA) for tocilizumab (Actemra) for treatment of hospitalized COVID-19 adults and children who are receiving systemic corticosteroids and supplemental oxygen. Since this announcement, the tocilizumab manufacturer, Genentech, has not been able to produce enough product to meet the higher demand. The…

20 Years of RA Data: First-Line Biologic & Targeted Synthetic DMARD Trends

Michele B. Kaufman, PharmD, BCGP  |  September 1, 2021

Data from a single-center registry shines light on 20 years of trends in first-line, biologic disease-modifying anti-rheumatic drug prescriptions for patients with rheumatoid arthritis.

  • « Previous Page
  • 1
  • …
  • 72
  • 73
  • 74
  • 75
  • 76
  • …
  • 332
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences